Bellevue Group AG Purchases 28,006 Shares of DexCom, Inc. (NASDAQ:DXCM)

Bellevue Group AG raised its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 2.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,045,044 shares of the medical device company's stock after purchasing an additional 28,006 shares during the quarter. DexCom makes up about 1.6% of Bellevue Group AG's portfolio, making the stock its 18th biggest holding. Bellevue Group AG owned 0.27% of DexCom worth $81,273,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in DXCM. Norges Bank acquired a new position in DexCom during the fourth quarter worth $385,367,000. Congress Asset Management Co. increased its stake in shares of DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock worth $105,529,000 after purchasing an additional 1,332,522 shares during the period. Fisher Funds Management LTD acquired a new stake in shares of DexCom during the fourth quarter worth $96,507,000. Northern Trust Corp boosted its holdings in DexCom by 22.2% in the 4th quarter. Northern Trust Corp now owns 4,146,249 shares of the medical device company's stock valued at $322,454,000 after purchasing an additional 753,857 shares during the period. Finally, Jennison Associates LLC increased its stake in DexCom by 10.3% during the 4th quarter. Jennison Associates LLC now owns 7,643,757 shares of the medical device company's stock worth $594,455,000 after acquiring an additional 710,858 shares during the period. Institutional investors own 97.75% of the company's stock.

Insider Buying and Selling

In other DexCom news, CEO Kevin R. Sayer sold 32,498 shares of the firm's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the transaction, the chief executive officer now directly owns 372,029 shares of the company's stock, valued at approximately $26,183,401.02. This trade represents a 8.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jacob Steven Leach sold 14,076 shares of the business's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $990,668.88. Following the sale, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at approximately $22,063,918.86. The trade was a 4.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 66,926 shares of company stock valued at $4,734,384 over the last 90 days. Company insiders own 0.32% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $85.00 to $115.00 in a research note on Monday, February 3rd. Barclays increased their price target on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research report on Monday. Morgan Stanley boosted their price objective on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a report on Thursday, January 16th. Finally, Cfra Research raised DexCom to a "hold" rating in a report on Friday, March 21st. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $98.11.

DexCom Trading Down 0.4 %

Shares of DexCom stock traded down $0.33 during midday trading on Friday, reaching $85.01. The company had a trading volume of 2,121,744 shares, compared to its average volume of 4,305,326. The firm has a market cap of $33.33 billion, a PE ratio of 59.45, a P/E/G ratio of 2.30 and a beta of 1.43. The stock has a fifty day moving average price of $71.03 and a 200 day moving average price of $77.09. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $132.26.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The firm had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same period in the prior year, the company posted $0.32 earnings per share. The company's revenue for the quarter was up 12.5% compared to the same quarter last year. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.